One-year treatment with mometasone furoate in chronic obstructive pulmonary disease

Respiratory Research

Table 2 Changes from baseline in pulmonary function*

	MF-DPI 800 μg QD PM 800(n = 275)	MF-DPI 400 μg BID (n = 278)	Placebo (n = 256)
Prebronchodilator FEV₁, L (pSD)
Longitudinal average	0.029 (0.182)^†	0.041 (0.182)^†	-0.034 (0.182)
ΔMF-DPI – placebo (95% CI)	0.063 (0.033–0.094)	0.075 (0.044–0.105)
Postbronchodilator FEV₁, L (SD)
Longitudinal average	0.050 (0.182)^†	0.053 (0.183)^†	-0.019 (0.176)
ΔMF-DPI – placebo (95% CI)	0.069 (0.040–0.098)	0.072 (0.044–0.102)
Prebronchodilator FEF_25%–75%, L/se(pSD)
Longitudinal average	0.027 (0.169)^‡	0.037 (0.169)^†	-0.016 (0.169)
ΔMF-DPI – placebo (95% CI)	0.043 (0.014–0.071)	0.053 (0.024–0.082)
Postbronchodilator FEF_25%–75%, L/s (pSD)
Longitudinal average	0.049 (0.185)^‡	0.042 (0.185)^‡	0.02 (0.185)
ΔMF-DPI – placebo (95% CI)	0.047 (0.015–0.079)	0.040 (0.09–0.072)
Prebronchodilator FVC, L (pSD)
Longitudinal average	0.031 (0.328)^†	0.045 (0.328)^†	-0.066 (0.328)
ΔMF-DPI – placebo (95% CI)	0.09 (0.042–0.153)	0.111 (0.056–0.166)
Postbronchodilator FVC, L (pSD)
Longitudinal average	0.066 (0.316)^†	0.044 (0.316)^‡	-0.028 (0.316)
ΔMF-DPI – placebo (95% CI)	0.094 (0.040–0.148)	0.072 (0.018–0.125)

BID = twice daily; FEF_25%–75% = forced expiratory flow between 25% and 75% of vital capacity; FEV₁ = forced expiratory volume in 1 second; FVC = forced vital capacity; MF-DPI = mometasone furoate administered via a dry powder inhaler; pSD = pooled standard deviation.
*This table shows spirometry results in subjects for whom both pre- and postbronchodilator data were available.
^†P < 0.001 vs placebo
^‡P ≤ 0.009 vs placebo

ISSN: 1465-993X